🌅 Pre-Market Pulse

S&P Futures 7,395.75 ▲ +5.00 (+0.07%)	Nasdaq Futures 28,731.50 ▲ +35.75 (+0.12%)	Dow Futures 50,048.00 ▼ -48.00 (-0.10%)
10Y Treasury 4.36% ▼ -0.06%	US Dollar 97.88 ▼ -0.16 (-0.16%)	Bitcoin $80,938 ▼ -$500 (-0.61%)

Good morning! Thursday, May 7 is serving up a genuinely interesting pre-market mix, with futures split in different directions and a handful of real catalysts to dig into. From a blockbuster pharma acquisition to Tesla's China comeback story and a geopolitical curveball aimed squarely at U.S. cloud giants, there is plenty pulling at attention this morning. Here is what is on the board before the bell rings.

👀 What to Watch Today

The macro calendar is worth keeping close today. Fed speakers are always a potential volatility trigger in this rate environment, especially with the 10-year yield sliding to 4.36% overnight, a move that is giving some lift to rate-sensitive growth names. Any commentary that leans hawkish could push back against that bond rally quickly.

On the deal front, the Angelini Pharma acquisition of Catalyst Pharmaceuticals (CPRX) for $4.1 billion closes out a busy M&A stretch in biopharma. Expect CPRX shares to command attention from the open as arbitrage traders price in the deal. Roche's (RHHBY) $750 million upfront acquisition of AI pathology firm PathAI is another one to watch, blending healthcare with artificial intelligence in a way that keeps the AI theme alive across multiple sectors.

Also worth monitoring: how European-exposed ETFs like BBEU and DBEU react to the cloud platform news out of Brussels. That story has longer legs than one trading session, and it could start moving sentiment in U.S. tech today.

The AI company beating every growth record ever set — get in for $10 [ad]

🌏 Overnight Recap

Overnight, the dominant headline came out of Europe, where CNBC reported that the European Commission is actively considering rules that would restrict U.S. cloud platforms from handling sensitive government data across EU member states. That is a direct shot across the bow for the hyperscalers, and while the formal policy is still in consideration, the signal from Brussels is unmistakably hostile toward American cloud dominance.

In Asia, Tesla's (TSLA) April China sales numbers landed with a thud, and it was a good thud. China-made EV deliveries jumped 36% year-on-year, marking the sixth consecutive month of annual gains. That is a meaningful data point for a company that has faced real competitive pressure from domestic rivals like BYD in the world's largest EV market.

Shell (SHEL) also reported overnight, beating profit expectations on the back of elevated fossil fuel prices tied to ongoing conflict in Iran. Oil market volatility is not going anywhere, and Shell's beat is a reminder that energy names are still benefiting from a geopolitically charged commodity backdrop.

Inside: Pre-IPO Ticker + The Next Elon Musk? [ad]

📊 Pre-Market Movers

CPRX is the most obvious pre-market story on the ticker tape this morning. Catalyst Pharmaceuticals is being acquired for $4.1 billion by Italy's Angelini Pharma, and shares are expected to spike hard toward the deal price at the open. When a small-cap biopharma gets a clean buyout offer at a premium, the trade is usually straightforward.

TSLA is worth watching closely after that China sales print. A 36% year-on-year jump in April is not a small number, and it comes at a time when the narrative around Tesla's international business has been under pressure. Pre-market enthusiasm could translate into real buying momentum if broader sentiment holds.

RHHBY, Roche's U.S.-traded ADR, may see some movement around the PathAI deal announcement. At $750 million upfront plus potential milestone payments, it is a meaningful commitment to AI-driven diagnostics, and the market will be deciding today whether Roche paid a fair price for the future.

Musk anoints the next NVIDIA?! [ad]

🔍 Today's Watchlist

1. TSLA: China EV sales up 36% year-on-year for six straight months. Pre-market momentum worth tracking into the open.
2. CPRX: Angelini Pharma's $4.1B acquisition puts Catalyst Pharmaceuticals squarely in focus for merger arb plays today.
3. SHEL: Shell's earnings beat on Iran-driven oil prices keeps the energy sector narrative alive heading into Thursday's session.
4. 10-Year Treasury at 4.36%: Yields are slipping, which historically provides a tailwind for tech and growth. Watch how that holds through the session.
5. U.S. Cloud Giants: The EU's potential data restrictions on American platforms could start pricing into sentiment for large-cap tech. Monitor BBEU and DBEF for European market reaction signals.

🎯 The Morning Playbook

The setup for Thursday is genuinely mixed, and that is not a bad thing. S&P and Nasdaq futures are in the green, the dollar is softening, and bond yields are easing, a combination that tends to favor growth and technology names. The Dow futures dipping slightly suggests some rotation pressure, but nothing alarming.

The real story to carry through today is the EU cloud platform news. If this policy framework moves forward, it has implications far beyond one morning's trade. American cloud providers generate significant revenue from European government contracts, and any forced localization or exclusion is a material business risk. Keep it on the radar even if it does not cause fireworks today.

Deals, defense, and data are the three threads running through this Thursday session. Markets reward preparation, and today the prep work is clear: know your levels, watch the movers, and stay sharp on the macro cross-currents. The edge goes to whoever is paying attention.

SpaceX IPO “cancelled”? [ad]